Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Hope for patients with advanced bowel cancer

21.10.2002


Early results of North American trials of chemotherapy drug oxaliplatin



For patients with bowel cancer that has spread to other organs despite treatment there has been little hope until now. However, early results of trials in North America of a chemotherapy drug called oxaliplatin, given in conjunction with two standard drugs, 5-FU and leucovorin, delay tumour progression by 70% compared with the control component of the study. There is also a significant improvement in the symptoms these patients experience.

Dr Mace Rothenberg from the Vanderbilt-Ingram Cancer Centre, Nashville, USA, lead a multi-centre trial in the USA involving 821 patients with advanced bowel – or colorectal - cancer to compare three different treatment strategies: 5-FU and leucovorin, oxaliplatin alone, or a combination of the drugs.


The delay in the progression and the shrinkage of the tumour lasted for a minimum of four weeks. "Both the delay in time to tumour progression and the reduction in tumour-related symptoms are very encouraging," said Dr Rothenberg, speaking at the European Society of Medical Oncology Congress in Nice, France, today (21 October 2002). "We found that patients suffered less from pain, weight loss and fatigue with the combination therapy."

The interim data from 463 patients were so promising that the US Food and Drug Administration gave its approval in August this year for oxaliplatin to be given to patients with advanced colorectal cancer that had progressed following first-line treatment. In Europe, however, oxaliplatin has been available since 1996. The drug is manufactured by Sanofi-Synthelabo in France.

Oxaliplatin can cause nausea, diarrhoea, anaemia and increased risk of infection, but on balance, the benefits appear to outweigh the side effects. 5-FU is given by intravenous drip and research is underway to find other easier means of delivery.

Bowel cancer affects nearly 150,000 people in the USA and around 35,000 people in the UK each year. It can arise in any part of the colon or rectum and is a leading cause of death.

"This trial should be fully mature in about six months. At that point we will know more about the impact of the oxaliplatin, 5-FU and leucovorin combination on the survival of patients with recurrent colorectal cancer," said Dr Rothenberg.

Gracemarie Bricalli | EurekAlert!

More articles from Health and Medicine:

nachricht Organ-on-a-chip mimics heart's biomechanical properties
23.02.2017 | Vanderbilt University

nachricht Researchers identify cause of hereditary skeletal muscle disorder
22.02.2017 | Klinikum der Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

From rocks in Colorado, evidence of a 'chaotic solar system'

23.02.2017 | Physics and Astronomy

'Quartz' crystals at the Earth's core power its magnetic field

23.02.2017 | Earth Sciences

Antimicrobial substances identified in Komodo dragon blood

23.02.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>